Hoth Therapeutics Files 8-K: Other Events Reported

Ticker: HOTH · Form: 8-K · Filed: 2025-09-12T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, regulatory-filing

TL;DR

HOTH filed an 8-K for 'Other Events' on 9/12/25 - details TBD.

AI Summary

Hoth Therapeutics, Inc. filed an 8-K on September 12, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the filing date itself.

Why It Matters

This filing indicates that Hoth Therapeutics has reported significant events to the SEC, but the lack of detail requires further investigation to understand the implications for the company.

Risk Assessment

Risk Level: medium — The filing is an 8-K for 'Other Events' without specific details, which can indicate significant but undisclosed developments, warranting a medium risk assessment.

Key Players & Entities

FAQ

What specific 'Other Events' are being reported by Hoth Therapeutics, Inc. in this 8-K filing?

The provided filing excerpt does not specify the nature of the 'Other Events' beyond the general category.

What is the significance of the filing date September 12, 2025, for Hoth Therapeutics, Inc.?

September 12, 2025, is the date the 8-K filing was made and the date of the earliest event reported.

What is Hoth Therapeutics, Inc.'s state of incorporation and fiscal year end?

Hoth Therapeutics, Inc. is incorporated in Nevada and has a fiscal year end of December 31.

Where is Hoth Therapeutics, Inc.'s principal executive office located?

The principal executive offices are located at 1177 Avenue of the Americas, 5th Floor, Suite 5066, New York, New York 10036.

What is the SEC file number and Central Index Key for Hoth Therapeutics, Inc.?

The SEC file number is 001-38803 and the Central Index Key is 0001711786.

From the Filing

0001213900-25-087054.txt : 20250912 0001213900-25-087054.hdr.sgml : 20250912 20250912081526 ACCESSION NUMBER: 0001213900-25-087054 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250912 ITEM INFORMATION: Other Events FILED AS OF DATE: 20250912 DATE AS OF CHANGE: 20250912 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hoth Therapeutics, Inc. CENTRAL INDEX KEY: 0001711786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 821553794 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38803 FILM NUMBER: 251310084 BUSINESS ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR SUITE 5066 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: (646)756-2997 MAIL ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR SUITE 5066 CITY: NEW YORK STATE: NY ZIP: 10036 8-K 1 ea0257020-8k_hoth.htm CURRENT REPORT false 0001711786 0001711786 2025-09-12 2025-09-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM  8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported)  September 12, 2025   Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter)   Nevada   001-38803   82-1553794 (State or other jurisdiction of incorporation)   (Commission File Number)   (I. R. S. Employer Identification No.)   1177 Avenue of the Americas , 5th Floor , Suite 5066 New York , New York 10036 (Address of principal executive offices, including ZIP code)   ( 646 )  756-2997 (Registrant’s telephone number, including area code)   Not Applicable (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, $0.0001 par value   HOTH   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company  ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐           Item 8.01 Other Events.   On September 10, 2025, Hoth Therapeutics, Inc.’s (the “Company’s”) board of directors approved the expansion of the Company’s previously announced treasury reserve strategy to include Ethereum and Solana. As such, the Company may purchase up to $1 million in Bitcoin, Ethereum and/or Solana as a treasury reserve asset, provided that the aggregate cost of such purchases does not exceed 20% of the Company’s cash on

View on Read The Filing